{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:43:54Z","timestamp":1792269834660,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04237-x","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:23Z","timestamp":1792224323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective analysis of treatment switch from faricimab to aflibercept 8 mg in nAMD"],"prefix":"10.1007","volume":"46","author":[{"given":"Sarah Nermin","family":"Mehany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia Veronika","family":"V\u00e9csei-Marlovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Boltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"4237_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/BJOPHTHALMOL-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M et al (2020) Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol 104:1077\u20131084. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2019-314422","journal-title":"Br J Ophthalmol"},{"key":"4237_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/JAMA.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U (2024) Age-related macular degeneration: a review. JAMA 331:147\u2013157. https:\/\/doi.org\/10.1001\/JAMA.2023.26074","journal-title":"JAMA"},{"key":"4237_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12886-018-0785-3\/FIGURES\/12","volume":"18","author":"CL Nguyen","year":"2018","unstructured":"Nguyen CL, Oh LJ, Wong E et al (2018) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol 18:1\u201315. https:\/\/doi.org\/10.1186\/S12886-018-0785-3\/FIGURES\/12","journal-title":"BMC Ophthalmol"},{"key":"4237_CR4","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s40123-025-01180-5","volume":"14","author":"D Tabano","year":"2025","unstructured":"Tabano D, Watane A, Gale R et al (2025) The economic burden of anti-vascular endothelial growth factor on patients and caregivers in the UK Europe, and North America. Ophthalmol Therapy 14:1869\u20131892. https:\/\/doi.org\/10.1007\/s40123-025-01180-5","journal-title":"Ophthalmol Therapy"},{"key":"4237_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"4237_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS et al (2024) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"4237_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/S10792-024-03297-1","author":"AA Aldhanhani","year":"2024","unstructured":"Aldhanhani AA, Azzam OA, AlAli SH et al (2024) Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration. Int Ophthalmol. https:\/\/doi.org\/10.1007\/S10792-024-03297-1","journal-title":"Int Ophthalmol"},{"key":"4237_CR8","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/S00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D et al (2024) Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 262:2153\u20132162. https:\/\/doi.org\/10.1007\/S00417-024-06421-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4237_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/S00417-023-06222-X","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N et al (2024) Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 262:43\u201351. https:\/\/doi.org\/10.1007\/S00417-023-06222-X","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4237_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3928\/23258160-20241205-01","volume":"56","author":"B Momenaei","year":"2025","unstructured":"Momenaei B, Yonekawa Y, Abril P et al (2025) Outcomes of intravitreal aflibercept 8 mg in eyes with neovascular age-related macular degeneration previously treated with faricimab. Ophthalmic Surg Lasers Imaging Retina 56:206\u2013211. https:\/\/doi.org\/10.3928\/23258160-20241205-01","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4237_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPHTH-2024-002091","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA (2025) Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol 10:e002091. https:\/\/doi.org\/10.1136\/BMJOPHTH-2024-002091","journal-title":"BMJ Open Ophthalmol"},{"key":"4237_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/LIFE15060903","volume":"15","author":"M Musadiq","year":"2025","unstructured":"Musadiq M, Musadiq M, Latif F et al (2025) Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life (Basel) 15:903. https:\/\/doi.org\/10.3390\/LIFE15060903","journal-title":"Life (Basel)"},{"key":"4237_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/J.XOPS.2023.100421","volume":"4","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Garmo V, Tabano D et al (2023) Impact of anti-VEGF treatment and patient characteristics on vision outcomes in neovascular age-related macular degeneration: up to 6-year analysis of the AAO IRIS\u00ae registry. Ophthalmol Sci 4:100421. https:\/\/doi.org\/10.1016\/J.XOPS.2023.100421","journal-title":"Ophthalmol Sci"},{"key":"4237_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004819","author":"HY Han","year":"2026","unstructured":"Han HY, Park SM, Kim CG et al (2026) Comparison of initial loading injection outcomes between aflibercept 8 mg and faricimab in neovascular age-related macular degeneration. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000004819","journal-title":"Retina"},{"key":"4237_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/IAE.0B013E3181BABDA5","volume":"30","author":"CK Chan","year":"2010","unstructured":"Chan CK, Abraham P, Meyer CH et al (2010) Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 30:203\u2013211. https:\/\/doi.org\/10.1097\/IAE.0B013E3181BABDA5","journal-title":"Retina"},{"key":"4237_CR16","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/IAE.0B013E31828992F5","volume":"33","author":"D Sarraf","year":"2013","unstructured":"Sarraf D, Chan C, Rahimy E, Abraham P (2013) Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy. Retina 33:1551\u20131557. https:\/\/doi.org\/10.1097\/IAE.0B013E31828992F5","journal-title":"Retina"},{"key":"4237_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1097\/IAE.0B013E31817D5D03","volume":"28","author":"A Chiang","year":"2008","unstructured":"Chiang A, Chang LK, Sarraf D (2008) Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 28:1265\u20131269. https:\/\/doi.org\/10.1097\/IAE.0B013E31817D5D03","journal-title":"Retina"},{"key":"4237_CR18","first-page":"142","volume":"112","author":"D Sarraf","year":"2014","unstructured":"Sarraf D, Joseph A, Rahimy E (2014) Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 112:142","journal-title":"Trans Am Ophthalmol Soc"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04237-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04237-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04237-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:02:56Z","timestamp":1792267376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04237-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4237"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04237-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the City of Vienna (Date 10.02.2025\/EK 25-010-VK).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No written consent was necessary as this was a retrospective data analysis.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"425"}}